NEW YORK (GenomeWeb) – Georgetown Lombardi Comprehensive Cancer Center and Hackensack University Medical Center's John Theurer Cancer Center (JTCC) today announced they will collaborate on cancer research.
The partners have developed a joint cancer research agenda as part of a multiyear plan to create a National Cancer Institute-recognized consortium. Proposed research projects include immuno-oncology and the sequencing of tumors with next-generation sequencing technologies.
"We are combining our strength in clinical care with Georgetown Lombardi's strong research base that significantly contributes to its clinical excellence," Hackensack University Health Network CEO Robert Garrett said in a statement. "By working together, we will elevate our cancer research to offer more treatment options."
The organizations said they have already identified several collaborative projects to work on. One will involve NGS tumor sequencing using the Clinical Outcomes Tracking & Analysis Platform that JTCC developed to find relevant populations for Phase I and II clinical trials.
Georgetown Lombardi is an NCI-designated comprehensive cancer center, a designation JTCC said it is working to secure.
Financial details of the agreement were not disclosed.
In January, Georgetown Lombardi joined the Caris Centers of Excellence for Precision Medicine Network, a consortium aiming to advance the delivery of tumor profiling and establish standards of care for molecular profiling in oncology.